One client says its her craving off-switch. Short Walk (5-10 Minutes): Step outside, even around your yard, and notice 3 thingsbirds chirping, a cool breeze, blooming flowers
Ranked by 2024 Global Sales: 1 Ozempic (semaglutide) $16.7 Bn | Novo Nordisk 2 Mounjaro (tirzepatide) $11.5 Bn | Eli Lilly 3 Jardiance (empagliflozin) $9.5 Bn | Boehringer Ingelheim & Eli Lilly 4 Forxiga (dapagliflozin) $7.7 Bn | AstraZeneca 5 Trulicity (dulaglutide) $5.3 Bn | Eli Lilly 6 Rybelsus (semaglutide) $3.2 Bn | Novo Nordisk 7 Humalog (insulin lispro) $2.3 Bn | Eli Lilly 8 NovoRapid (insulin aspart) $2.3 Bn | Novo Nordisk 9 Jentadueto / Trajenta (linagliptin) $1.8 Bn | Boehringer Ingelheim Lantus (insulin glargine) $1.7 Bn | Sanofi Key Insight: The dominance of incretin-based therapies underscores a clear industry shift toward multi-benefit, patient-centric treatments
Back Manalac, T (23 Dec 2024) '7 Indications for GLP-1s beyond weight loss', BioSpace
The Sequential Approach A reasonable strategy is starting with semaglutide and escalating to tirzepatide if needed
Yang et al
They also show promise for the treatment of many inflammatory diseases including asthma and inflammatory bowel disorders like Crohns disease and ulcerative colitis Diagram showing food stimulating the release of GLP-1 into the intestine and its effects on the brain, stomach and pancreas Importance In 2023 GLP-1 based drugs was named breakthrough of the year by Science , a prestigious American journal
